Cessation Therapeutics

Executive Summary

Cessation Therapeutics is a privately held biotechnology company headquartered in San Jose, California, focused on developing a novel antibody-based therapy to combat the fentanyl overdose crisis. With fentanyl being the leading cause of death for Americans aged 18 to 45, the company has pioneered an anti-fentanyl monoclonal antibody treatment designed to prevent overdose from fentanyl and its potent analogs. The therapy aims to bind and neutralize fentanyl in the bloodstream, thereby blocking its effects on the central nervous system. Founded in 2021, Cessation is addressing a critical public health emergency with a biologic approach that could offer a safer alternative to current opioid reversal agents like naloxone, particularly against the high-potency synthetic opioids responsible for tens of thousands of deaths annually. The company's research and development efforts are focused on advancing this antibody through preclinical and early clinical stages, leveraging its proprietary platform to generate high-affinity antibodies capable of rapid fentanyl sequestration. While financial details and specific developmental milestones have not been publicly disclosed, the therapeutic potential of an anti-fentanyl antibody has garnered significant attention from both public health authorities and investors seeking solutions to the opioid epidemic. The company's progress in preclinical studies and subsequent clinical validation will be critical in determining its ability to deliver a life-saving intervention.

Upcoming Catalysts (preview)

• Q4 2026IND submission for anti-fentanyl monoclonal antibody70% success
• TBDInitiation of Phase 1 clinical trial60% success
• Q3 2026Preclinical efficacy data publication80% success